<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20016">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846324</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-006</org_study_id>
    <nct_id>NCT02846324</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF
      subjects will be randomized to receive GBT440 or Placebo orally daily.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Days 1 to 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of GBT440 including maximum concentration</measure>
    <time_frame>Days 1 to 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of GBT440 including minimum concentration</measure>
    <time_frame>Days 1 to 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of GBT440 including apparent terminal half life</measure>
    <time_frame>Days 1 to 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of GBT440 on oxygen saturation using pulse oximetry at rest</measure>
    <time_frame>Screening to Day 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of GBT440 on oxygen saturation using pulse oximetry after exercise</measure>
    <time_frame>Screening to Day 58</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>GBT440 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <description>Capsules which contain GBT440 drug substance in Swedish orange</description>
    <arm_group_label>GBT440 Dose 1</arm_group_label>
    <arm_group_label>GBT440 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of IPF.

          -  Oxygen desaturation with exercise.

          -  Completion of the baseline 6MWT

          -  Weight â‰¥ 50 kg

          -  Male or female of child bearing potential willing and able to use highly effective
             methods of contraception from study start to 3 months after the last dose of study
             drug.

        Exclusion Criteria:

          -  FEV1/FVC &lt; 70%.

          -  Subjects on supplemental oxygen therapy at rest.

          -  History of other interstitial lung diseases.

          -  Significant polycythemia.

          -  Female who is breast-feeding or pregnant.

          -  Known current malignancy or history of malignancy within the last 2 years prior to
             screening.

          -  Use of cytotoxic and/or immunosuppressant medications within 30 days screening.

          -  Hospitalization due to an exacerbation of IPF within 30 days of screening

          -  Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of
             screening

          -  Corticosteroids (&gt; 10 mg per day of prednisone or an equivalent) within 30 days of
             screening.

          -  Current smoker or history of smoking within 3 months of screening.

          -  Currently or, in the opinion of the investigator, soon to be listed for lung
             transplant.

          -  History of unstable or deteriorating cardiac or pulmonary disease (other than IPF)
             within 6 months of screening.

          -  Any condition possibly affecting drug absorption.

          -  Participated in another clinical trial of an investigational drug (or medical device)
             within 30 days or 5-half-lives, whichever is longer, prior to screening, or is
             currently participating in another trial of an investigational drug (or medical
             device).

          -  Subject who, for any reason, is deemed by the investigator to be inappropriate for
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Vlahakis, M.D.</last_name>
    <phone>650-741-7730</phone>
    <email>nvlahakis@globalbloodtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharonda Keazor</last_name>
      <phone>205-975-8335</phone>
      <email>skeazor@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darren Leong</last_name>
      <phone>415-353-2296</phone>
      <email>darren.leong@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Burnside</last_name>
      <phone>303-398-1554</phone>
      <email>burnsidel@njhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Simonet</last_name>
      <phone>305-243-6372</phone>
      <email>esimonet@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marla Watson</last_name>
      <phone>913-588-4022</phone>
      <email>mwatson5@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Glynn</last_name>
      <phone>504-988-0743</phone>
      <email>cglynn1@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amika McBurnie</last_name>
      <phone>212-342-1518</phone>
      <email>akm2192@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Johnson</last_name>
      <phone>215-707-4679</phone>
      <email>sylvia.johnson@tuhs.temple.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Warden</last_name>
      <phone>843-792-2081</phone>
      <email>jonesash@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim DelGreco</last_name>
      <phone>615-343-7068</phone>
      <email>james.del.greco@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Weaver</last_name>
      <phone>801-587-7855</phone>
      <email>lisa.weaver@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwinia Battle</last_name>
      <phone>703-776-3067</phone>
      <email>edwinia.battle@inova.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>July 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
